Open AccessCardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression
Author(s) -
Pantelis A. Sarafidis,
Luís M. Ruilope
Publication year - 2012
Publication title -
jraas. journal of the renin-angiotensin-aldosterone system/journal of the renin-angiotensin-aldosterone system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 46
eISSN - 1752-8976
pISSN - 1470-3203
DOI - 10.1177/1470320312439140
Subject(s) - cardiorenal syndrome , renin–angiotensin system , medicine , aldosterone , disease , angiotensin ii , cardiology , endocrinology , heart failure , receptor , blood pressure
Drugs suppressing the renin-angiotensin-aldosterone system (RAAS) are now widely used to treat patients all along the cardiorenal continuum. It supposes that many patients, in particular those with arterial hypertension are treated with converting-enzyme inhibitors and angiotensin receptor blockers for years during which the development and prograssion of cardiorenal disease can be observed. The meaning of this progression in the presence of RAAS suppression requires to be clarified and to be treated in order to diminish the velocity of progression of cardiorenal disease.